Dear Sir, Elevated levels of homocysteine have been found to predict cardiovascular events. 1 Severe hyperhomocysteinemia is uncommon and can result from homozygosity of cystathionine b-synthase (CBS) or methylenetetrahydrofolate reductase (MTHFR) deficiency. Therefore, heterozygosity for these enzyme defects has been proposed as a major cause of moderate hyperhomocysteinemia. However, the frequency of heterozygosity for CBS and MTHFR deficiency is too low to account for the frequency of mildly elevated homocysteine levels in patients with cardiovascular disease. 2 The more common moderate elevation of homocysteine may result from nutrient deficiencies (folate, vitamins B 12 , and B 6 ) or less severe genetic disorders in enzymes involved in the transulphuration or remethylation pathways for homocysteine metabolism. 3 In 1995, Frosst et al 4 identified a missense mutation in which a cytosine residue at position 677 of the MTHFR gene is replaced by thymine. The mutation results in a substitution of alanine by valine, and individuals homozygous or heterozygous for such mutation have decreased specific MTHFR activity and increased thermolability of the enzyme. In addition, persons who are homozygous for the above-mentioned variation have significantly elevated plasma homocysteine levels. From the analysis of the biological mechanisms that explains the homocysteine-cardiovascular disease hypothesis, it would be possible to predict a positive association between homocysteine and blood pressure. 5 However, there is no clear and consistent evidence that associates homocysteine and hypertension.
Then, following the hypothesis that hyperhomocysteinemia and the related MTHFR genotypes may be associated with essential hypertension, in an elderly population, We (i) examined the prevalence of both hyperhomocysteinemia and the C677T MTHFR mutation, (ii) correlated the corresponding genotypes with the levels of homocysteine and (iii) analysed the association of these variables with essential hypertension. As the effect of age and diet may weaken the statistic power of the analysis, we perform the same study on an adolescent population-based sample.
Adult hypertensive subjects originated from a sample of all outpatients visiting a hypertension clinic of a county hospital at Buenos Aires. A complete examination including electrocardiographic, echocardiographic, biochemical, and anthropometric measurements were performed on a total of 302 men and women attended (35 and 65%, respectively), aged: 57.8 7 10.1 years. Secondary hypertension, other cardiovascular or renal diseases were considered exclusion criteria. Diabetic patients or patients with nephropathies were also excluded from the study. Of the patients who met the inclusion criteria, a total of 119 hypertensive subjects and 53 spouse controls accepted to participate and gave an informed consent. The Ethical Committee of the Hospital approved the study. All subjects responded to a questionnaire on medical history, physical activities, medication, and personal habits. Body mass index (BMI) was computed as weight in kilograms divided by height in meter squared (kg/m 2 ). Hypertension was defined as systolic blood pressure (SBP) 4160 mmHg or diastolic blood pressure (DBP) 495 mmHg, or when subjects were taking long-term antihypertensive medication; and normotension was defined as BP values below 140/90 mmHg.
In addition, we interviewed 934 adolescents from a high school student population at an inner city (Chacabuco, Province of Buenos Aires) who also responded to the same questionnaire. Anthropometric variables were also measured. Based on the average of two measurements separated by 5 min of resting BP normalized as a Z-score according to sex and age using the USA Task force tables, 6 we selected 105 and 115 adolescents who have SBP/ DBP in these first measurements over 80th and under 20th percentiles, respectively, and invited them to participate in a further study. A total 175 subjects who accepted to participate underwent two additional BP measurements on different days, biochemical analysis and genotyping as described below. Adolescents having an average of SBP/DBP over 95th percentile and with no causes of secondary hypertension, other cardiovascular diseases, connective tissue or renal diseases, or diabetes (basal glycaemia 46.1 mmol/l) were considered essential hypertensives, and 54 met this criterion. The remaining 121 were considered as controls.
Blood was drawn from fasting subjects who were in a supine resting position for at least 30 min. Plasma glucose, insulin, total cholesterol, high-and low-density lipoproteins (HDL and LDL), triglycerides, aldosterone, and plasma renin activity (PRA) were measured by standard clinical laboratory techniques.
Total plasma homocysteine concentrations were determined by an HPLC method using a commercially available kit (Bio-Rad Laboratories, Hercules, CA, USA). According to manufacturers, we used a cutoff normal value of 15 mmol/ml.
Genomic DNA was extracted from white blood cells by a standard method using proteinase K. MTHFR polymorphism was detected by a hot-start polymerase chain reaction (PCR/RFLP) by a previously published method. 4 Quantitative variable distributions were assessed by the Shapiro-Wilk test. If they were normally distributed, data were expressed as mean 7 s.d. and analysed by Student's t-test, otherwise results were analysed with the Mann-Whitney U-test and expressed as median (IQR). Logistic regression was used for testing the association between hyperhomocysteinemia and hypertension, C677T MTHFR genotypes and other independent covariates. Genotype frequencies were analysed by means of a w 2 test. Correlation between variables was assayed by the Spearman R correlation coefficient test. Table 1 shows the clinical characteristics of the elderly normotensive and hypertensive subjects.
Hypertensives have a significantly higher BMI and left ventricular mass. Although they were nondiabetic, hypertensive patients also showed a significant decrease in plasma insulin and a slightly enhanced fasted glycaemia with a significant decrease in insulin/glucose ratio suggestive of a decreased insulin secretion rate.
MTHFR genotype frequencies were in agreement with that previously reported in Caucasian populations and did not differ from those expected according to the Hardy-Weinberg equilibrium. There were no significant differences between the genotype frequencies of the two groups (data not shown). On the other hand, hyperhomocysteinemia was highly prevalent in our elderly population showing a frequency of 30.6%, although there was no difference in plasma homocysteine levels between hypertensives and normotensives (Table 1 ) or in the frequencies of hyperhomocysteinemia between the two groups (normotensives: 29.0% and hypertensives: 31.1%). In the entire sample, we found a significant correlation of homocysteinemia with age and glycaemia (Spearman R: 019 and 0.17, Po0.02 and o0.03, respectively).
As in the elderly population, age and dietary factors may have an important influence on plasma homocysteine levels, we further investigate the association of this variable with essential hypertension in an adolescent population-based study. As can be seen in Table 1 , hypertensive adolescents show a higher pulse pressure, BMI, plasma insulin, insulin/glucose ratio, plasma triglycerides, and lower HDL levels than normotensives. In addition, there was a significant difference in homocysteinemia levels between the two groups (Table 1) , and the frequency of hyperhomocysteinemia was significantly higher in hypertensive (16%) with respect to normotensive (3%) subjects (BMI-adjusted OR: 4.44, 95% CI: 1.12-17.6, Po0.03). In these young populations, MTHFR C677T genotypes were also in Hardy-Weinberg equilibrium and did not significantly differ from those found in the elderly subject samples. Although MTHFR genotype frequencies in hypertensives were not different from those observed in normotensives (data not shown), hyperhomocysteinemia was associated with the T variant of the MTHFR gene (OR: 9.01, 95% CI: 2.24-36.1, Po0.002). In a multiple logistic regression analysis, the MTHFR allele and hypertension were associated with hyperhomocysteinemia after adjustment for sex and BMI (OR: 3.75, 95% CI: 1.35-10.42, Po0.01 and OR: 6.65, 95% CI: 1.51-29.29, Po0.01, respectively).
The studies showing elevated basal homocysteine levels as correlated among family members of patients with coronary artery disease and juvenile venous thrombosis suggested the possibility of an inherited basal mild hyperhomocysteinemia as one of the causes of these vascular diseases. In 1995, Boushey et al 7 concluded from a meta-analysis of 27 relevant publications that homocysteine is an independent risk factor for arteriosclerotic vascular disease unrelated to hyperlipidaemia, hypertension, diabetes, and smoking. Since then, multiple prospective and case-control studies had shown that a moderately elevated plasma homocysteine concentration is an independent risk factor for atherothrombotic vascular disease. As with cholesterol levels, the risk is graded; the risk rises with increasing homocysteine levels, although it was not yet clear whether homocysteine itself or a related metabolite or cofactor is primarily responsible for these effects. On the other hand, polymorphism of the MTHFR gene is probably an important factor, 5 although Brattstrom et al 8 found no association between MTHFR genotypes and risk of vascular events. The growth-promoting effect of homocysteine on vascular smooth muscle cells, together with its inhibitory effect on endothelial cell growth, may explain homocysteine-induced atherosclerosis. 9 In addition, high levels of homocysteine may induce an increase in oxidative stress, which in turn can produce endothelium dysfunction. [10] [11] [12] The mechanisms of injury appear to involve oxidative damage to endothelial cells, although other authors 13 suggest that a direct action on smooth muscle cells may also be involved. Vascular wall remodelling and endothelial dysfunction through a decrease in vasodilator release such as nitric oxide and prostacyclin or an increase in vasoconstrictor production, for instance endothelin, may induce hypertension 14 . Therefore, we have hypothesized that hyperhomocysteinemia and the related MTHFR genotypes may be associated with essential hypertension. In our elderly population, the prevalence of hyperhomocysteinemia was high and we found a significant correlation of homocysteine with age and glycaemia. For these individuals, there was no difference in plasma homocysteine levels between hypertensives and normotensives. However, the lack of association between hyperhomocysteinemia and hypertension in the adult population could be caused by the effects of confounding factors such as diet and age.
The mutation of MTHFR reported by Frosst et al 4 is also common in the Argentinian population and the resulting genotype frequencies show a distribution that is compatible with the Hardy-Weinberg equilibrium. As a result of the above-mentioned confounding factors, it is not surprising that we found no association between the C677T polymorphism of the MTHFR gene and homocysteine levels and/or hypertension in this elderly population. For these reasons and to strengthen the statistical power of our study, we further investigated these associations in a sample of adolescent individuals from a population-based cohort from a different geographic region. In this very young population, the prevalence of hypertension was high with an estimated value of 5%. The fact that hypertensive adolescents had larger BMI and waist:-hip ratios, dyslipidaemia and increased insulin/ glucose ratios may suggest that these subjects are suffering from the so-called metabolic syndrome that may have both environmental and genetic determinants. 15 Then, we found that the frequency of hyperhomocysteinemia was significantly higher in hypertensive subjects (16%) than in normotensives (3%). Accordingly, hypertensive adolescents had significantly higher homocysteine levels than normotensive ones. These findings are not striking because although the evidence linking hyperhomocysteinemia with hypertension is limited and inconsistent, 5, [16] [17] [18] it is possible to predict a positive association between homocysteine and blood pressure in view of the above-described biological mechanisms proposed in support of the homocysteine-cardiovascular disease hypothesis. In addition, we found that the MTHFR genotypes, which are also in the Hardy-Weinberg equilibrium, are similar to those from the older and geographically separated population. Thus, a cumulative body of evidence suggests that this mutation is highly prevalent beyond ethnic groups and can be regarded as a balanced polymorphism that escaped natural selection. On the other hand, in our adolescent population we found that hyperhomocysteinemia is associated with the C677T polymorphism of the MTHFR gene, suggesting that this genetic variation could be one of the factors that may increase the cardiovascular risk for hypertensive individuals by elevating plasma homocysteine levels. However, we could not demonstrate a direct association between the C677T MTHFR polymorphism and hypertension indicating that other genetic and/or environmental factors may be important in modulating the associa-tion between hyperhomocysteinemia and essential hypertension or a lack of power enough to detect small differences. Finally, a note of caution: a causative link cannot be established from a crosssectional study since confounding factors such as folate/vitamin B 6 /vitamin B 12 status or minimal alterations in renal function may explain the differences between groups.
To conclude, our results suggest that homocysteine may be associated with young-onset essential hypertension. Since diet supplementation with folic acid, vitamins B 6 and B 12 decreases or even normalizes plasma homocysteine concentrations in most cases, 19 prospective, randomized clinical trials would be necessary to determine the effect that vitamin supplementation may have on hypertension incidence.
